Developing low-carbon metered-dose inhalers: effects of propellant HFA-152a on mucociliary clearance and bronchoconstriction in two Phase 1 randomised trials.
Dave Singh, Italo Poggesi, Stephen Weng et al.
✦ AI-curated · Sources linked
In 30 seconds
This study evaluated the effects of the low-global warming potential propellant HFA-152a compared to HFA-134a on mucociliary clearance and bronchoconstriction in two Phase 1 randomized trials. In 22 healthy participants, HFA-152a showed no significant difference in mucociliary clearance (AUC 0-4h geometric mean ratio: 1.00 [0.99, 1.01]). In 19 patients with mild asthma, HFA-152a was non-inferior to HFA-134a regarding bronchoconstriction (mean difference: 0.23% [-3.61, 4.07]).
Key findings
- Mucociliary clearance was similar for HFA-152a and HFA-134a (AUC 0-4h geometric mean ratio: 1.00 [0.99, 1.01]).
- Neither propellant induced bronchoconstriction in asthma patients (-0.37% for HFA-152a vs -0.60% for HFA-134a).
- HFA-152a was non-inferior to HFA-134a in terms of bronchoconstriction (mean difference: 0.23% [-3.61, 4.07]).
- Adverse event rates were low and similar for both propellants, with all events being mild.
Why it matters
The findings support the potential for reformulating metered-dose inhalers with HFA-152a, which could significantly reduce the environmental impact of respiratory care without compromising safety or efficacy in mucociliary clearance and bronchoconstriction.